Abstract
Abstract
Background
Each year 3–6 million people develop life-threatening severe dengue (SD). Clinical warning signs for SD manifest late in the disease course and are nonspecific, leading to missed cases and excess hospital burden. Better SD prognostics are urgently needed.
Methods
We integrated 11 public datasets profiling the blood transcriptome of 365 dengue patients of all ages and from seven countries, encompassing biological, clinical, and technical heterogeneity. We performed an iterative multi-cohort analysis to identify differentially expressed genes (DEGs) between non-severe patients and SD progressors. Using only these DEGs, we trained an XGBoost machine learning model on public data to predict progression to SD. All model parameters were “locked” prior to validation in an independent, prospectively enrolled cohort of 377 dengue patients in Colombia. We measured expression of the DEGs in whole blood samples collected upon presentation, prior to SD progression. We then compared the accuracy of the locked XGBoost model and clinical warning signs in predicting SD.
Results
We identified eight SD-associated DEGs in the public datasets and built an 8-gene XGBoost model that accurately predicted SD progression in the independent validation cohort with 86.4% (95% CI 68.2–100) sensitivity and 79.7% (95% CI 75.5–83.9) specificity. Given the 5.8% proportion of SD cases in this cohort, the 8-gene model had a positive and negative predictive value (PPV and NPV) of 20.9% (95% CI 16.7–25.6) and 99.0% (95% CI 97.7–100.0), respectively. Compared to clinical warning signs at presentation, which had 77.3% (95% CI 58.3–94.1) sensitivity and 39.7% (95% CI 34.7–44.9) specificity, the 8-gene model led to an 80% reduction in the number needed to predict (NNP) from 25.4 to 5.0. Importantly, the 8-gene model accurately predicted subsequent SD in the first three days post-fever onset and up to three days prior to SD progression.
Conclusions
The 8-gene XGBoost model, trained on heterogeneous public datasets, accurately predicted progression to SD in a large, independent, prospective cohort, including during the early febrile stage when SD prediction remains clinically difficult. The model has potential to be translated to a point-of-care prognostic assay to reduce dengue morbidity and mortality without overwhelming limited healthcare resources.
Funder
Dr. Ralph and Marian Falk Medical Research Trust
U.S. Department of Defense
SPARK at Stanford
Stanford Bio-X
National Institute of Allergy and Infectious Diseases
Bill and Melinda Gates Foundation
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine
Reference77 articles.
1. WHO. Dengue and severe dengue. Geneva: World Health Organization; 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue. Accessed 10 Dec 2020.
2. Xin Tian C, Baharuddin KA, Shaik Farid AW, Andey R, Ridzuan MI, Siti-Azrin AH. Ultrasound findings of plasma leakage as imaging adjunct in clinical management of dengue fever without warning signs. Med J Malaysia. 2020;75(6):635–41 Epub 2020/11/22. PubMed PMID: 33219170.
3. Rafi A, Mousumi AN, Ahmed R, Chowdhury RH, Wadood A, Hossain G. Dengue epidemic in a non-endemic zone of Bangladesh: Clinical and laboratory profiles of patients. PLoS Negl Trop Dis. 2020;14(10):e0008567 Epub 2020/10/14. doi: 10.1371/journal.pntd.0008567. PubMed PMID: 33048921; PubMed Central PMCID: PMCPMC7553334.
4. Shepard DS, Undurraga EA, Halasa YA, Stanaway JD. The global economic burden of dengue: a systematic analysis. Lancet Infect Dis. 2016;16(8):935–41. https://doi.org/10.1016/S1473-3099(16)00146-8.
5. Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16(6):712–23. https://doi.org/10.1016/S1473-3099(16)00026-8.
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献